GLPwatch
Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes.
Ann Intern Med · 2017
Last updated 2026-05-28| Journal | Ann Intern Med, 2017 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.03 |
| NIH percentile | 4 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Full record and abstract on PubMed 29255857 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.